Efficacy of Treatment for Gestational Diabetes Diagnosed by the IADPSG Criteria.

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes Prevention

Pregnancy Complications

Treatment

N/A

Clinical Study ID

NCT02708758

CONACYT 233634

212250-3402-10102-02-14

Ages 18-45
Female

Study Summary

There is a lack of international uniformity in the approach to the screening and diagnosis of gestational diabetes mellitus (GDM). The new diagnostic criteria by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) based on data from the study of Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) have created controversy because of the lack of clinical evidence of treatment benefit for mild GDM and the treatment effects on perinatal outcomes. The purpose of the present study is to know the efficacy of treatment to reduce adverse pregnancy outcomes in Mexican women diagnosed with GDM by IADPSG criteria.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Singleton pregnancy between 18-30 week´s gestation
75-g oral glucose-tolerance test at 20-30 week´s gestation with only one altered valuebetween: Fasting 92-99 mg/dL

hour 180-211 mg/dL
hour 153-177 mg/dL

Exclusion

Exclusion Criteria:

Pregestational diabetes (first diagnosed in pregnancy) defined by altered valuesduring 75-g oral glucose-tolerance test above: Fasting >126 mg/dL 2 hour >200 mg/dL

-Two or more altered values during oral glucose tolerance test above: Fasting 92 mg/dL

hour 180 mg/dL
hour 153 mg/dL

Multiple pregnancy
Active chronic systemic disease as hyperthyroidism, hearth, hepatic or renaldisease, immunological disease as lupus and chronic hypertension

Study Design

March 01, 2016

December 31, 2021

Study Description

Currently no evidence from randomized clinical trials on the efficacy of treatment of gestational diabetes mellitus (GDM), diagnosed by a single altered value during a 75g oral glucose tolerance test (75g OGTT), proposed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) to reduce adverse perinatal outcomes (APO). In our institution GDM diagnosis is established with two or more altered values during 75g OGTT, women with one altered value during OGTT are not considered GDM and therefore those women do not receive specific treatment for GDM. We conduct an open randomized clinical trial, two groups, Group 1 (women with treatment for GDM) and group 2 (women with routine care). The diagnosis of GDM will be perform with a single altered value during 75g OGTT: fasting ≥ 92mg / dL, 1-hour ≥ 180 mg / dL and 2-hours ≥ 153 mg / dL. Treatment consist of medical nutritional therapy (MNT), which includes restricted diet 45% carbohydrate, exercise and self-monitoring of glucose, if not reach therapeutic goals metformin and / or insulin will be added.

Connect with a study center

Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Mexico City, 11000
Mexico
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.